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Abstract
Although there are indications for modulatory effects of PUFA on associations between SNP and obesity risk, scientific evidence in human
subjects is still scarce. The present analyses investigated interaction effects between SNP in candidate genes for obesity and PUFA in eryth-
rocyte membranes on obesity risk. Within the second Bavarian Food Consumption Survey (cross-sectional, population-based), 568 adults
provided blood samples. Fatty acid composition of erythrocyte membranes was analysed by means of GC. Genotyping was performed for
twenty-one genes, including cytokines, adipokines, neurotransmitters and transcription factors. In addition, plasma IL-6 concentrations
were analysed. For the statistical analysis, a logistic regression model assuming additive genetic effects was chosen. About 20 % of the
study participants were classified as obese (BMI $30 kg/m2). Several significant gene–PUFA interactions were found, indicating regulatory
effects of PUFA by gene variants of IL-2, IL-6, IL-18, TNF receptor family member 1B and 21, leptin receptor and adiponectin on obesity
risk. After stratification by genotype, the strongest effects were found for rs2069779 (IL-2) and all tested PUFA as well as for rs1800795 (IL-6)
and linoleic or arachidonic acid. The obesity risk of minor allele carriers significantly decreased with increasing fatty acid content. The
genetic PUFA–IL-6 interaction was also reflected in plasma IL-6 concentrations. If replicated in a prospective study with sufficient statistical
power, the results would indicate a beneficial effect of high PUFA supply for a substantial proportion of the population with respect to
obesity risk.
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Obesity is a multifactorial disorder reflecting complex inter-
actions of genes, environment and lifestyle(1). Industrialisation
and modernisation encourage a sedentary lifestyle with con-
comitantly increased energy intake, resulting in an imbalance
of energy intake and expenditure(2) and consequently in gain-
ing surplus weight. About 40–70 % of the variance in the BMI
is accounted for by genetic factors as several studies of twins,
adoptees and families have shown(3–5). Screenings of candi-
date regions as well as genome-wide scans have helped to
identify SNP that increase the risk of becoming overweight
or obese(6).
There is considerable evidence that not all fatty acids are
obesogenic(7). Approximately 6·2–7·4 % of our average daily
energy intake is accounted for by PUFA (n-3 PUFA 0·7–
0·9 %; n-6 PUFA 5·5–6·5 %)(8). PUFA exert their influence on
cardiovascular function, insulin action, plasma lipid levels(9),
neuronal development and the immune system inter alia
through modulation of eicosanoid (PG and leukotrine) syn-
thesis, activation of orphan nuclear receptor and T-lympho-
cyte signalling(9,10). They also regulate the transcription and
activation of multiple genes(11–13). Hence, PUFA affect several
metabolic pathways, and thus may have an impact on the
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development of a series of diseases, including obesity(13,14)
either directly or through interactive effects with the genetic
background. This is supported by the results of different
experimental studies(15–18).
So far, only a few studies have investigated gene–PUFA
interactions with respect to obesity risk. We have mainly
found human or animal cell studies or dietary intervention
studies showing PUFA to have an increasing or decreasing
effect on the expression of different candidate genes
for obesity. Reseland et al.(17), for example, found n-3 PUFA
to decrease leptin gene expression in a dose- and time-
dependent manner within a human trophoblast cell line.
Alnajjar et al.(19) described the effects of PUFA on the IL
production on the basis of a dietary intervention study
(Jordan population). A case–control study in the European
Prospective Investigation into Cancer and Nutrition by Nieters
et al.(20) has obtained indications for possible interactive
effects between dietary intake of PUFA and polymorphisms
of different obesity candidate gene variants.
Obesity is the result of an interaction between genetic
predisposition and the modern obesogenic environment(21).
As it is spreading rather rapidly and presenting a major
health problem, it is important to understand inter-individual
variance and susceptibility. Thus, the aim of the present
study is to investigate potential interactions between PUFA
and selected SNP with respect to their impact on obesity risk.
Within the present study, twenty-one candidate genes for
obesity, including cytokines, neurotransmitters, transcription
factors and adipokines, were selected. Interaction effects with
regard to obesity risk were calculated for the fatty acid compo-
sition of the erythrocyte membranes, a biomarker for dietary
PUFA intake, and SNP located within these gene regions. The
PUFA composition of the erythrocyte membranes reflects both
PUFA intake and subsequent metabolism of the fatty acids
over a period of weeks and months(22). In order to lend more
credence to the statistical results of the genetic IL-6–PUFA
analyses, plasma IL-6 concentrations were also considered.
Methods
Study design and population
The second Bavarian Food Consumption Survey is a cross-
sectional study, representative of the Bavarian population and
designed to investigate dietary and lifestyle habits. German-
speaking subjects (n 1050) aged 13–80 years were recruited
between September 2002 and June 2003 following a three-
step random route sampling procedure. A total of forty-two
communities served as sampling points and were stratified
by county and community characteristics. With a given start
address, a random walk (every third household) was con-
ducted and one random household member who met the
inclusion criteria was selected. Information on the subjects’
characteristics, lifestyle as well as health and socio-economic
status were collected during a personal computer-assisted
face-to-face interview at baseline. The participation rate
was 71 %. A non-responder analysis was preformed. On aver-
age, non-responders had – among other characteristics – a
higher BMI than the study participants. Within the following
two weeks, data of the subjects’ dietary intake and physical
activity (PA) were assessed by three 24 h dietary recalls (two
weekdays and one weekend day), which were conducted
via telephone and by trained interviewers. For the 24 h
dietary recalls, the software EPIC-Soft (International Agency
for Research on Cancer, Lyon, France) was used(23–25). The
participants had to recall their dietary intake as well as their
PA of the previous day. All adult subjects ($18 years) who
completed at least one 24 h recall (n 879) were invited
to their nearest public health office for blood sampling and
standardised anthropometric measurements within 6 weeks
after recruitment. Of these subjects, 65 % (n 568) accepted
this invitation and represented the subgroup on which this
evaluation is based on. The study was conducted according
to the guidelines laid down in the Declaration of Helsinki,
and all procedures involving human subjects were approved
by the local ethics committee. Written informed consent was
obtained from all study participants.
Anthropometric, dietary and physical activity assessment
Height was measured to the nearest 0·5 cm and weight to the
closest 0·5 kg. BMI was calculated as weight/height2 (kg/m2).
Subjects were classified according to the definition of the
WHO(26) as obese (BMI $30 kg/m2) and non-obese (BMI
,30 kg/m2). Hip size was determined as the widest circumfer-
ence measured over the buttocks and waist measurements
were taken midway between the iliac crest and the margin
of the lower rip.
The German food composition table BLS (Bundeslebensmit-
telschlüssel) (version II.3; BgVV, Berlin, Germany) was used to
calculate nutrient intake. Data were weighted correspondingly
to weekday or weekend day in order to calculate a mean daily
intake per subject.
In the telephone interviews, participants were asked to
recall their PA of the last 24 h. Standardised questions on
type and duration of the PA in the categories of sports, occu-
pation and other strenuous activities during leisure time as
well as non-occupational television/personal computer use
and duration of sleeping were part of the computer-based
interview. Metabolic equivalents (MET) were matched to
each activity and the energy expenditure (MET £ h) of every
individual was estimated(27).
Blood sampling
Venous blood was drawn, chilled at 48C and further processed
within 3 h. Plasma and buffy coat were separated from eryth-
rocytes by centrifugation (2000 g for 15 min) before being
divided into aliquots and stored at 2808C for further analyses.
Fatty acid composition of erythrocyte membranes
Membrane fatty acid analysis was conducted using an aliquot
of 0·5 ml erythrocyte suspension. After cell lyses through
addition of aqua destillata, the erythrocyte membranes were
isolated via centrifugation (20 000g for 20 min at 48C) and
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the pellet was resuspended with Tris-buffer (11 mM-Tris, 1 mM-
Na-EDTA, pH 7·4); the washing procedure was repeated twice
before adding 800ml aqua destillata(28). Fatty acid extraction
was performed using a mixture of chloroform and methanol
(2:1, v/v) according to a modification of the method described
by Folch et al.(29). The lipids were extracted twice using a
chloroform–methanol mixture with the added antioxidant
butylated hydroxytoluene (50 mg/l)(30). The combination of
these extracts was washed with a CaCl2 solution. The organic
phase was collected and evaporated until dry. Resuspension
of that extract was done using chloroform, and via trans-
esterification with trimethylsulphonium hydroxide, the fatty
acid methyl esters were obtained(31).
A 100 m CP-Sil-88 capillary column (Varian-Chrompack,
Darmstadt, Germany), which was installed in an HP 5890
series II gas chromatograph with a flame-ionisation detector
(Hewlett Packard, Munich, Germany), was used to identify
and separate the different fatty acid methyl esters. Authentic
standards (Sigma-Aldrich, Steinheim, Germany) were applied
to assure a correct identification and quantification of the
fatty acid methyl ester peaks. As a result, the content of
twenty-two types of fatty acids was measured and is expressed
as a percentage of the total fatty acid methyl esters (% fatty
acid methyl esters) identified(32). For each sample, data
represent the mean of two injections.
Analysis of plasma IL-6
Plasma IL-6 was measured by means of a commercial ELISA
kit (Biosource, Brussels, Belgium). The intra- and inter-assay
CV were below 7 and 9 %, respectively.
SNP selection
The genetic dataset was developed in 2006 and consists of
different candidate genes, which were chosen on the basis
of an extensive literature research. SNP covering these genes
as well as 100 kb of region 50 and 50 kb of region 30 were
selected based on hapmap data (www.hapmap.org; phases
1 and 2) with a minimum minor allele frequency of 0·05
according to the data of dbSNP Build 125 (an SNP database).
For the present analyses, we carefully selected only genes
for which an indication of a potential interaction with
PUFA was provided by the literature. These include different
cytokines and their receptors (IL-2, IL-6, IL-10, IL-18, TNF-a,
TNFRSF1A, TNFRSF1B and TNFRSF21 (TNF receptor super-
family 1A, 1B and 21)), neurotransmitters and their receptors
(NPY (neuropeptide Y), NPY1R, NPY5R (NPY receptors
Y1 and Y5), MC4R (melanocortin 4 receptor), POMC (pro-
opiomelanocortin), PPY (pancreatic polypeptide), and PYY
(peptide YY)), transcription factors (PPARg and PPARgC1A)
and adipokines (LEP (leptin), LEPR (leptin receptor),
ADIPOQ (adiponectin) and RETN (resistin)). For these
genes, the genetic dataset holds a total number of 187 SNP,
consisting of 180 tagging SNP, eighteen coding SNP and
twelve candidate SNP previously reported to be associated
with obesity. The median number of SNP per gene locus is
11 with a range of 2–16.
Genotyping and quality control
Genotyping was performed by GoldenGate Genotyping Assay
(Illumina, Inc., San Diego, CA, USA) according to the standard
protocol of the manufacturer. Additional inclusion criteria
were a minor allele frequency of at least 5 % and genotyping
call rate of not less than 95 %, leaving 157 SNP in the dataset.
Statistical analyses
The descriptive data are presented as median with 25 and 75 %
quantiles for continuous parameters, as the majority of the
variables were not normally distributed, or as percentage
and absolute frequency for qualitative variables. Comparisons
between the groups of obese and non-obese subjects were
made by means of either the Mann–Whitney U test (continu-
ous variables) or the Kruskal–Wallis test (qualitative para-
meters). Socio-economic status was categorised based on the
values of three characteristics on a point scale including
educational level, social position and the households’ net
income(33). PA data represent the estimated overall energy
expenditure (MET £ h) of every individual(27).
Departure from the Hardy–Weinberg equilibrium was
tested by means of an exact test(34). All selected SNP were
in the Hardy–Weinberg equilibrium except for rs1061624
(TNFRSF1B), rs16475 (NPY), rs16480 (NPY region 50) and
rs17366743 (ADIPOQ), applying a P value of 3·09£ 1024
(corrected for multiple testing) as the significance level.
For comparison of the allele frequencies between obese
and non-obese subjects, a Kruskal–Wallis test was used. The
main effects of SNP and PUFA as well as their interaction
effects are derived from a logistic regression model assuming
additive genetic effects, and are presented as OR with the cor-
responding 95 % CI. For the genetic main-effect models, SNP
were introduced as discrete parameters with either three
categories (homozygous wild type, heterozygous or homo-
zygous mutant type) or two categories (homozygous wild
type and one or more mutant allele carriers), depending on
the number of subjects in the third category (homozygous
mutant type; minimum of ten subjects). As EPA and DHA
were highly correlated, their sum was used in the present
analyses. The fatty acid variables (presented as percentage
of fatty acid methyl esters) were established as continuous
parameters. For the interaction models, both SNP and PUFA
were introduced as continuous parameters. A likelihood
ratio test was used to compare the models with and without
an interaction term and a P value of ,0·05 was regarded as
nominally statistically significant. These P values are denoted
as Pint. The interaction models were adjusted for sex, age,
PA and socio-economic status and significant SNP–PUFA
interactions were analysed further. The effect of each PUFA
with respect to obesity risk was estimated within the gene
strata (homozygous wild type and one or more mutant allele
carriers) of the SNP using logistic regression models adjusted
for sex, age, PA and socio-economic status. As the analyses
were done within the SNP strata and the number of people
carrying two minor alleles was often quite small, two cate-
gories were used for sample size reasons. We tried different
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procedures, inter alia by Bonferroni, Holm, Hochberg, Sidak
or Benjamini and Hochberg, to correct the present results
for multiple testing, but neither left us with any significant
result. Therefore, all P values reported in the present study
are uncorrected and only nominally significant at a 5 %. The
SNP were tested for pairwise linkage disequilibrium (LD).
If SNP were in high LD (r 2 $ 0·7), one of them was selected
as representative for the LD block. We chose rs1800795 to
represent the IL-6 LD block with rs1800797 (r 2 0·935) and
rs2069833 (r 2 0·967) and IL-18 SNP rs3882891 to represent
rs1946519 (r 2 0·77).
As five values of plasma IL-6 were declared as outliers
(greater than mean plus five times the standard deviation),
they were excluded from the analyses. While plasma IL-6
levels ranged between 0·25 and 11·64 pg/ml, the levels of
those five outliers were substantially higher (51·5, 61·8,
68·92, 93·62 and 620·6 pg/ml). The reason for those high
values could neither be clarified nor was a re-analysis of the
samples possible. To account for skewness, the parameter
was log-transformed. Plasma IL-6 is presented as geometric
means and 95 % CI. All statistical analyses were performed
with R software version 2.9.0 (R Development Core
Team, 2009; http://www.r-project.org/).
Results
Table 1 summarises the characteristics of the study population.
Obese subjects had a median BMI of 33·04 (25–75 % quantiles
31·19–36·12) kg/m2 and their median age exceeded that of the
non-obese subjects (median BMI of 24·83 (25–75 % quantiles
22·55–27·20) kg/m2) by 12 years. The median hip and waist
circumference of obese and non-obese participants differed
by 12·5 and 22·5 cm and the plasma IL-6 level of obese sub-
jects was also elevated. There was no significant difference
Table 1. Characteristics of obese (BMI $30 kg/m2) and non-obese (BMI ,30 kg/m2) subjects in a subsample of the Bavarian Food Consumption
Survey II
(Medians, 25–75 % quartiles, percentages or number of absolute frequencies)
Obese subjects (20·07 %) Non-obese subjects (79·93 %)
Parameters % Absolute n % Absolute n P *
Sex 0·6373
Male 44·74 51 42·29 192
Female 55·26 63 57·71 262
Age groups (years) ,0·0001
18 to ,30 5·26 6 11·45 52
30 to ,40 12·28 14 25·55 116
40 to ,50 14·91 17 23·79 108
50 to ,65 42·98 49 23·79 108
$ 65 24·56 28 15·42 70
Socio-economic status ,0·0001
Lower class 22·81 26 33·26 151
Lower middle class 14·91 17 22·69 103
Middle class 5·26 6 10·79 49
Upper middle class 36·84 42 20·93 95
Upper class 20·18 23 12·33 56
Median 25–75 % Quantiles Median 25–75 % Quantiles P†
Age (years) 56·00 44·25–64·00 44·00 36·00–61·00 ,0·0001
Weight (kg) 94·30 83·55–94·55 70·10 62·28–78·27 ,0·0001
Height (cm) 165·00 159·00–173·00 168·00 163·00–174·00 0·0050
BMI (kg/m2) 33·04 31·19–36·12 24·83 22·55–27·20 ,0·0001
Waist (cm) 112·00 106·00–120·50 89·50 81·50–98·75 ,0·0001
Hip (cm) 117·50 114·00–125·00 105·00 100·00–109·00 ,0·0001
Waist:hip ratio 0·95 0·89–1·00 0·86 0·79–0·92 ,0·0001
Physical activity (MET £ h/d) 37·24 34·45–40·20 37·74 35·30–42·14 0·1163
Erythrocyte membranes
Linoleic acid (% FAME in erythrocytes) 10·98 9·40–12·12 11·50 10·44–12·51 0·0044
Arachidonic acid (% FAME in erythrocytes) 15·86 9·16–17·63 15·99 12·84–17·57 0·3436
EPAþDHA (% FAME in erythrocytes) 5·63 1·79–7·56 6·19 4·06–7·58 0·2297
Dietary intake
Energy intake (kJ/d) 7420 5805–9363 8229 6459–9875 0·0137
Linoleic acid (% E) 4·85 3·78–6·71 5·08 3·83–6·58 0·8279
Arachidonic acid (% E) 0·72 0·52–0·99 0·66 0·43–0·99 0·1477
EPAþDHA (% E) 0·046 0·03–0·15 0·043 0·02–0·14 0·2417
Plasma concentration‡
IL-6 (pg/ml) 2·37 2·12–2·65 1·38 1·30–1·48 ,0·0001
MET, metabolic equivalents; % FAME in erythrocytes, fatty acids in percentage of total fatty acid methyl esters in erythrocyte membranes; % E, percentage of energy.
* Kruskal–Wallis test.
† Mann–Whitney U test.
‡ Values are geometric means and 95 % CI.
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in sex distribution, PA or dietary fatty acid intake between the
two groups. The linoleic acid (LA), arachidonic acid (AA), and
EPAþDHA compositions of erythrocyte membranes were
higher for non-obese (v. obese) participants but only the
difference in LA content reached statistical significance.
The following results are not corrected for multiple testing
and therefore are only nominally significant at a 5 %. Table
S1 of the supplementary material (available online at http://
www.journals.cambridge.org/bjn) shows the distribution of
the alleles within the two groups of obese and non-obese sub-
jects, the P-values of the Kruskal–Wallis test and the main
effects of all SNP analysed on the risk of obesity. Risk esti-
mates were calculated for models with either three categories
(homozygous wild type, heterozygous and homozygous
mutant type) or two categories (homozygous wild type and
one or more mutant allele carriers). The P value of the con-
tinuous model is also given as a P trend. A nominal P value
,0·05 was reached by rs4719714 and rs12700386 (IL-6
region 50), rs2069849 (IL-6), rs1061628 (TNFRSF1B) and
rs1116656 (LEP region 30). The crude main effects for LA
(OR 0·90, 95 % CI 0·83, 0·98), AA (OR 0·97, 95 % CI 0·93,
1·01) and EPAþDHA (OR 0·96, 95 % CI 0·89, 1·03) in erythro-
cytes showed an indication of an inverse association with
obesity, but only for LA, the statistical significance was
reached.
SNP for which the interaction term with PUFA reached nom-
inal statistical significance (a 5 %) were stratified by genotype
(two categories: homozygote wild type and one or more
mutant allele carriers), and risk estimates were calculated for
the corresponding PUFA within these strata (Tables 2–4) .
Concerning cytokine genes, we found several SNP–PUFA
interactions in relation to obesity risk. For IL-2, the interaction
term between rs2069779 and all three PUFA as well as
between rs2069762, rs4833248 (IL-2 region 50) and LA were
statistically significant. Each PUFA associated with rs2069779
had a decreasing effect on obesity risk for minor allele carriers
(Fig. 1). In this gene stratum, the risk decreased for each mol %
increase in erythrocyte membrane-bound PUFA with OR of
0·63 (LA), 0·83 (AA) and 0·66 (EPAþDHA). For rs4833248 as
well as rs2069762, homozygous wild-type carriers benefited
from increased LA content in erythrocyte membranes. Ana-
lyses for IL-6 revealed three SNP: rs1800795; rs10242595;
rs2069861. The first two showed a significant interaction
effect with LA with Pint ¼ 0·0341 and 0·0315, respectively.
For each percentage increase in erythrocyte membrane-bound
LA, obesity risk decreased in carriers of at least one minor
allele of rs1800795 with an OR of 0·86 (95 % CI 0·76, 0·96); a
similar effect was found for the rs1800795–AA interaction
(Fig. 2). In the case of rs10242595, the relative risk decreased
for carriers of the homozygous wild-type alleles with increas-
ing LA content (OR 0·81, 95 % CI 0·71, 0·93). The interaction
effect of rs2069861 and EPAþDHA was significant as well.
Here, the obesity risk decreased with each mol % increase of
erythrocyte membrane-bound EPAþDHA for minor allele car-
riers (OR 0·74, 95 % CI 0·57, 0·94). For IL-18, one SNP
(rs3882891) interacted significantly with LA when analysing
obesity risk. Minor allele carriers of this SNP had a reduced
obesity risk with increasing LA content in erythrocyte mem-
branes (OR 0·84, 95 % CI 0·75, 0·94, Pint ¼ 0·0203).
We also obtained evidence for SNP–EPAþDHA interaction
effects of the TNFRSF1B gene. Subjects carrying at least one
minor allele of rs3766730 (OR 0·86, 95 % CI 0·75, 0·98,
Pint ¼ 0·0225) or rs2275416 (OR 0·88, 95 % CI 0·78, 0·99,
Pint ¼ 0·0455) had a lower obesity risk than homozygous
wild-type carriers. In relation to obesity risk, two SNP
of TNFRSF21 were shown to interact with EPAþDHA;
rs9381530 (region 30) with an OR of 0·79 (95 % CI 0·68, 0·91,
Pint ¼ 0·0065) and rs2236039 with an OR of 0·87 (95 % CI
0·78, 0·96, Pint ¼ 0·0482). In each case, obesity risk decreased
with increasing PUFA content in subjects carrying two
major alleles.
Among the selected adipokine genes, few significant results
were obtained. The interaction terms of two ADIPOQ SNP
(rs1063539 and rs2241766) and membrane EPAþDHA
content were significantly associated with obesity risk. In
homozygous wild-type carriers, obesity risk decreased with
Table 2. Significant SNP–linoleic acid interactions on obesity risk, showing the adjusted* relative risk of obesity
per 1 mol% increase of linoleic acid† in erythrocyte membranes by allelic variants
(Odds ratios and 95 % confidence intervals)
Genes SNP Allele Non-obese (%) Obese (%) OR 95 % CI* Pint‡
IL-2 rs2069779 CC 85·8 86·7 0·93 0·85, 1·03 0·031
$1 T 14·2 13·3 0·63 0·42, 0·87
IL-2 rs2069762 TT 49·6 51·8 0·84 0·73, 0·96 0·0381
$1 G 50·4 48·2 0·96 0·85, 1·10
IL-2 region 50 rs4833248 GG 48·3 50·9 0·81 0·70, 0·94 0·0192
$1 A 51·7 49·1 0·96 0·85, 1·10
IL-6 rs1800795 GG 33·6 35·4 0·98 0·84, 1·14 0·0341
$1 C 66·4 64·6 0·86 0·76, 0·96
IL-6 region 30 rs10242595 AA 49·2 50·0 0·81 0·71, 0·93 0·0229
$1 G 50·8 50·0 0·98 0·87, 1·12
IL-18 rs3882891 AA 35·0 32·5 1·03 0·88, 1·22 0·0237
$1 C 65·0 67·5 0·83 0·74, 0·94
LEPR rs1805096 CC 37·5 36·8 1·01 0·85, 1·20 0·0084
$1 T 62·5 63·2 0·83 0·74, 0·93
* Adjusted for age, sex, physical activity and socio-economic status.
† Main effect: OR 0·90, 95 % CI 0·82, 0·99.
‡P value of the likelihood-ratio test (adjusted continuous interaction model).
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increasing EPAþDHA content (Table 4). Concerning a leptin
receptor gene polymorphism (rs1805096), an inverse associ-
ation with obesity risk existed in carriers of the minor allele,
with an increasing erythrocyte membrane content of LA (OR
0·83, 95 % CI 0·74, 0·93, Pint ¼ 0·0084; Table 2) or AA (OR
0·95, 95 % CI 0·91, 1·00, Pint ¼ 0·0459; Table 3).
Table 5 gives the geometric means and the 95 % CI of
plasma IL-6 stratified by IL-6 SNP rs1800795, rs10242595 and
rs2069861 (homozygote wild type and one or more mutant
alleles) and tertiles of LA, AA and EPAþDHA for obese and
non-obese subjects. The plasma IL-6 concentrations were
generally higher in obese subjects compared with non-obese
subjects (see also Table 1) and decreased with increasing
PUFA content in erythrocyte membranes (tertiles). These
results lend credit to the identified IL-6 SNP–PUFA interactions
and obesity risk derived from the statistical models.
Discussion
The present study aimed to investigate the additional effect on
obesity brought on by the interaction of selected genetic
variants and PUFA content of erythrocyte membranes. Out
of the four different groups of genes, including cytokines,
adipokines, neurotransmitters and transcription factors, we
obtained significant interaction effects between the SNP of
IL-2, IL-6, IL-18, TNFRSF1B, TNFRSF21, LEPR or ADIPOQ
and PUFA content in erythrocyte membranes. We found a
reduced obesity risk for minor allele carriers of most variants
with high PUFA content in erythrocyte membranes, except
for the SNP of TNFRSF21, ADIPOQ, rs2069762 (IL-2),
rs4833248 (IL-2 region 50) and rs10242595 (IL-6 region 30).
With the latter genes, subjects, homozygote for the major
allele, benefited from an increased PUFA content of erythro-
cyte membranes. In the case of IL-6, the analysed plasma
IL-6 protein concentration supports the statistical findings.
Obesity has been described as a state of chronic low-grade
inflammation(35,36). Thus, polymorphisms in different cyto-
kines were included in the analyses of gene–PUFA inter-
actions. Cytokines are a group of modulatory proteins which
respond to various stimuli, thereby activating second messen-
gers and signal transduction pathways within the cells(37).
Several cell studies and also dietary intervention studies
have shown a reduced production of IL-2 in response
to PUFA(16,18,19,38); however, the exact mechanism behind
this phenomenon still remains unclear(39,40). In the present
study, obesity risk decreased with increasing PUFA content
Table 3. Significant SNP–arachidonic acid interactions on obesity risk, showing the adjusted* relative risk
of obesity per 1 mol% increase of arachidonic acid† in erythrocyte membranes by allelic variants
(Odds ratios and 95 % confidence intervals)
Genes SNP Allele Non-obese (%) Obese (%) OR 95 % CI* Pint‡
IL-2 rs2069779 CC 85·8 86·7 1·00 0·95, 1·04 0·0104
$1 T 14·2 13·3 0·83 0·72, 0·94
IL-6 rs1800795 GG 33·6 35·4 1·01 0·94, 1·08 0·0315
$1 C 66·4 64·6 0·96 0·91, 1·01
LEPR rs1805096 CC 37·5 36·8 1·01 0·94, 1·10 0·0459
$1 T 62·5 63·2 0·95 0·91, 1·00
* Adjusted for age, sex, physical activity and socio-economic status.
† Main effect: OR 0·97, 95 % CI 0·94, 1·01.
‡P value of the likelihood-ratio test (adjusted continuous interaction model).
Table 4. Significant SNP–EPAþDHA interactions on obesity risk, showing the adjusted* relative risk of obesity per
1 mol% increase of EPAþDHA† in erythrocyte membranes by allelic variants
(Odds ratios and 95 % confidence intervals)
Genes SNP Allele Non-obese (%) Obese (%) OR 95 % CI* Pint‡
IL-2 rs2069779 CC 85·8 86·7 1·00 0·93, 1·09 0·0021
$1 T 14·2 13·3 0·66 0·48, 0·85
IL-6 rs2069861 CC 80·4 86·8 1·00 0·92, 1·08 0·0219
$1 T 19·6 13·2 0·74 0·57, 0·94
TNFRSF1B rs3766730 CC 71·0 69·9 1·01 0·93, 1·11 0·0237
$1 T 29·0 30·1 0·86 0·74, 0·99
TNFRSF1B rs2275416 GG 67·9 62·8 1·02 0·93, 1·11 0·0341
$1 A 32·1 37·2 0·88 0·77, 1·00
TNFRSF21 region 30 rs9381530 TT 30·7 35·1 0·79 0·68, 0·91 0·0065
$1 G 69·3 64·9 1·03 0·95, 1·13
TNFRSF21 rs2236039 AA 53·3 49·1 0·87 0·78, 0·96 0·0482
$1 G 46·7 50·9 1·06 0·95, 1·17
ADIPOQ rs2241766 TT 77·8 85·1 0·92 0·85, 1·00 0·0040
$1 G 22·2 14·9 1·19 0·96, 1·52
ADIPOQ rs1063539 GG 72·7 80·5 0·92 0·85, 1·00 0·0316
$1 C 27·3 19·5 1·09 0·92, 1·32
* Adjusted for age, sex, physical activity and socio-economic status.
† Main effect: OR 0·95, 95 % CI 0·89, 1·02.
‡P value of the likelihood-ratio test (adjusted continuous interaction model).
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of the erythrocyte membranes, and thus confirms the expected
direction. PUFA eicosanoid derivates, such as PGE2, are
involved in the modulation of the intensity and duration of
inflammatory processes and suppress the production of
IL-6(10). Adipose tissue in human subjects releases IL-6 and
serum levels are positively correlated with body fat mass(41).
Himmerich et al.(42) confirmed this relation for the present
population. IL-6 gene transcription was found to be influ-
enced in vitro by the rs1800795 polymorphism within the
promoter region(43). The G allele of this SNP was described
as to be more common in lean subjects(44); additionally, a
lower BMR was measured in subjects with the CC geno-
type(45), which might eventually predispose to weight gain;
this hypothesis has been supported by some studies but not
confirmed in two meta-analyses of the association of this
SNP with BMI(46,47). Our findings on SNP–PUFA interactions
may provide an explanation for the diverging results since
they consider the possible interplay between the SNP and
PUFA supply status. For the other IL-6 SNP, rs10242595, the
A variant was found to be significantly associated with
decreased fat mass in young adult men, a result which was
replicated in two other population-based studies of elderly
men(48). The interaction effect between this SNP and PUFA
in the present study is indicative towards the importance of
this SNP for the development of obesity. Variations in the
IL-18 gene have been associated with IL-18 plasma concen-
trations and measures of obesity(49). Obese subjects show
higher levels of IL-18 than lean subjects(50), and IL-18 has
been associated with excess adiposity(51). Our IL-18 variant
is in complete LD with rs5744292, an IL-18 SNP whose
minor allele has been reported to be associated with lower
circulating IL-18 levels and lower mRNA expression in immor-
talised lymphocytes(52,53). Furthermore, a suppressing effect
of PGE2 on the expression of IL-18 has been shown in
cell studies(54). The finding of an IL-18–PUFA interaction in
the present study fits well with these data. Even though the
production of TNF-a by monocytes and macrophages is also
suppressed through PGE2
(10), no significant interactions
could be determined within the present study. However,
we found evidence for significant interaction effects for its
receptors, TNFRSF1B and TNFRSF21.
Overall, all identified (significant) interactions between
cytokine SNP and PUFA indicate an inverse association
with obesity risk for minor allele carriers, with increasing
PUFA content in erythrocyte membranes, except for SNP of
TNFRSF21, rs4833248 (IL-2 region 50) and rs10242595 (IL-6
region 30).
Besides its role for lipid storage, adipose tissue functions as
an endocrine organ, regulating metabolism and different vital
functions related, among others, to inflammation(55,56). Thus,
different adipokines have been included in the present ana-
lyses. Adiponectin is exclusively secreted by adipose tissue
and serum levels are inversely correlated with body fat
mass(57). The mRNA expression is reduced in obese individ-
uals(58). Serum adiponectin levels are highly heritable
(approximately 50 %) and are linked to the ADIPOQ gene
locus(59–61). Different cell and dietary intervention studies
found EPAþDHA to stimulate the expression of ADIPOQ
and to increase plasma adiponectin levels(62–64); however,
findings differ(65). EPAþDHA might possibly up-regulate
ADIPOQ by acting through PPARg, affecting the ADIPOQ
promoter(15). The present results are in line with these findings
and show a significantly decreased obesity risk for carriers of
two major alleles of rs2241766 or rs1063539, with increasing
EPAþDHA concentrations in erythrocyte membranes. Differ-
ent animal, human and cell studies have shown an inverse
effect of PUFA on the LEP mRNA expression(17,66). The present
analyses resulted in one significant interaction for a variant of
the leptin receptor gene, which is in line with these findings.
We see two major mechanisms of how PUFA may in con-


















Fig. 1. Effect of linoleic acid ( , Pint ¼ 0·0310), arachidonic acid
( , Pint ¼ 0·0104) and EPAþDHA ( , Pint ¼ 0·0022) on the risk of obesity,
stratified by genotype of IL-2 (rs2069779). Estimates are adjusted for age,
sex, physical activity and socio-economic status. Pint, P value of the likeli-

















Fig. 2. Effect of linoleic acid ( , Pint ¼ 0·0341), arachidonic acid
( , Pint ¼ 0·0315) and EPAþDHA ( , Pint ¼ 0·0878) on the risk of obesity,
stratified by genotype of IL-6 (rs1800795). Estimates are adjusted for
age, sex, physical activity and socio-economic status. Pint, P value of the
likelihood-ratio test comparing models with and without an interaction term.
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direct modification of gene transcription or by products of the
eicosanoid pathway. To compare the direction of the different
effects of PUFA on the risk of obesity within the SNP strata of
the significant interaction models, we also estimated the
effects of the remaining PUFA by the given SNP strata for
which the interaction term with those SNP was not significant
(e.g. Fig. 2). We observed quite similar effects (direction and
estimates) over the different PUFA in the various SNP strata
(data not shown). A high erythrocyte membrane content of
LA or AA or EPAþDHA thereby did either show no association
or an inverse association with obesity risk in each of the SNP
strata. Therefore, we conclude that PUFA exert their effects
rather via modification of gene transcription than through
metabolites derived during eicosanoid synthesis, since the
latter would have led to differential effects of n-3 and n-6
PUFA. In mutually adjusted analyses, we have also not
received any indication for changes of effects of n-3 PUFA-
adjusted n-6 PUFA and vice versa. It is important to mention
that the frequency of these SNP for which we observed inter-
active effects with PUFA is fairly high, except for IL-2 SNP
(rs2069779). This implicates that a substantial part of the
population would benefit from a high PUFA intake with
respect to obesity risk.
A major limitation of the present study is obviously the small
sample size. Studies of genetic associations with complex dis-
eases need thousands of cases and controls(67); however, this
requirement is not easily fulfilled with respect to the costly
fatty acid analyses. The small number of cases and controls
and consequently the limited statistical power strongly argue
for a careful interpretation of the results and a replication
in a second, larger and independent study. Because of the
small sample size and the resulting limited power, we did
not correct for multiple testing. No correction method for
multiple testing left us with any significant result. Therefore,
all reported P values are not corrected and are only nominally
significant at a 5 %. The observational nature of the study
does not allow for interpreting causal associations, and we
cannot rule out the possibility of reverse causation. However,
we controlled for potential confounding by adjusting for
sex, age, PA and socio-economic status.
The major strength of the present study is the use of
erythrocyte membranes to assess biologically available PUFA
at the cellular level and its association with genetic variants
influencing the risk of obesity. With the utilisation of bio-
markers as an objective metabolic correlate of dietary PUFA
intake, misclassifications can be largely avoided. A further
strength of the present study is its population-based design
aiming at representativeness for the adult Bavarian population
and the strict quality control in the analyses.
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